Merck + Co., Inc.

Clare E Gutteridge

William K Hagmann

Alan D Adams

Stephen E De Laszlo

A Brian Jones

Sheo B Singh

Yuan Cheng

Theodore M Kamenecka

James Francis Dropinski

Bruno Tse

John G Ondeyka

Shaei Y Huang

Aileen Bouffard

Weiguo Lui

Ali Shiafee

Ahren I Green

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol. 

Therapeutic compounds for treating dyslipidemic conditions

Compounds of Formula Iand the pharmaceutically acceptable salts and esters thereof, wherein Z is selected from the group consisting of:

Compounds of Formula I are antagonists of VLA-4 and/or &agr; &bgr; , and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

Substituted isonipecotyl derivatives as inhibitors of cell adhesion

Substituted nipecotyl derivatives as inhibitors of cell adhesion

Growing community of inventors

Annapolis, MD, United States of America

Clare E Gutteridge